당뇨병 치료제 시장 : 제품, 용도, 유통 채널별 - 세계 예측(2025-2030년)

The Diabetes Drugs Market was valued at USD 69.12 billion in 2023, expected to reach USD 72.97 billion in 2024, and is projected to grow at a CAGR of 5.88%, to USD 103.18 billion by 2030.

The diabetes drugs market encompasses pharmaceuticals aiming to improve blood sugar levels in individuals with diabetes, including type 1, type 2, and gestational diabetes. This market has become increasingly crucial as the prevalence of diabetes globally is rising due to factors like sedentary lifestyles, unhealthy diets, and aging populations. The core applications and end-use scope of diabetes drugs involve managing blood glucose levels to mitigate the risk of acute and long-term complications, improving the quality of life for patients. Market insights reveal that key growth influencers include the continuous advancements in drug formulation, increasing awareness about diabetes management, and substantial investments in healthcare infrastructure. Moreover, the increasing incidence of diabetes in emerging economies presents potential opportunities for market expansion. Latest opportunities can be found in the development of personalized medicine and digital tools that offer comprehensive diabetes management solutions. However, limitations challenging market growth include stringent regulatory frameworks, side effects associated with diabetes medication, and the high cost of advanced therapeutic drugs, which may limit access in low-income regions. Areas poised for innovation include enhancing drug delivery systems, such as smart insulin pens, and the integration of artificial intelligence in diabetes management to enhance therapeutic outcomes. Furthermore, the development of novel therapeutic classes, including SGLT2 inhibitors and GLP-1 receptor agonists, continues to shape the market landscape. It's also noteworthy that collaboration between pharmaceutical companies and tech firms could facilitate the creation of more innovative, integrated solutions. In essence, the market is dynamic and ripe with potential, driven by technological advances and a growing need for more efficacious and accessible diabetic care solutions. However, capturing these opportunities necessitates overcoming regulatory and cost barriers, emphasizing the importance of strategic investment in research and development to propel business growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Diabetes Drugs Market

The Diabetes Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of diabetes globally
  • Government Initiatives and supportive health policies for diabetes
  • Growing research and development activities for advanced drug formulations
• Market Restraints
  • High cost of diabetes medications and complexity of diabetes management
• Market Opportunities
  • Emerging collaborations among research labs and pharmaceutical companies
  • Rising demand for personalized medicine among consumers
• Market Challenges
  • Stringent government approval procedures

Porter's Five Forces: A Strategic Tool for Navigating the Diabetes Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Diabetes Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Diabetes Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Diabetes Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Diabetes Drugs Market

A detailed market share analysis in the Diabetes Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Diabetes Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Diabetes Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Diabetes Drugs Market

A strategic analysis of the Diabetes Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Diabetes Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Astellas Pharma Inc., AstraZeneca PLC, Baxter International, Inc., Bayer AG, Biocon Limited, Bioton S.A., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, Eva Pharma, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Limited, Gulf Pharmaceutical Industries (Julphar), Johnson & Johnson Services, Inc., Lupin Limited, MannKind Corporation, Merck & Co., Inc., MJ Biopharm Pvt. Ltd., Novartis AG, Novo Nordisk A/S, Oramed Pharmaceuticals Inc., Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Tonghua Dongbao Pharmaceutical Co., Ltd., Viatris Inc., and Zydus Lifesciences Limited.

Market Segmentation & Coverage

This research report categorizes the Diabetes Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Insulin, Non-Insulin Injectable Drugs, and Oral Drug. The Insulin is further studied across Intermediate-Acting Insulin, Long-Acting Insulin, Premixed Insulin, Rapid-Acting Insulin, and Short-Acting Insulin. The Non-Insulin Injectable Drugs is further studied across Amylin Analogs and GLP-1 Receptor Agonists. The Oral Drug is further studied across Biguanides, DPP-4 inhibitors, SGLT-2 inhibitors, Sulfonylureas, and Thiazolidinediones.
• Based on Application, market is studied across Gestational Diabetes, Type 1 Diabetes, and Type 2 Diabetes.
• Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of diabetes globally
    • 5.1.1.2. Government Initiatives and supportive health policies for diabetes
    • 5.1.1.3. Growing research and development activities for advanced drug formulations
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of diabetes medications and complexity of diabetes management
  • 5.1.3. Opportunities
    • 5.1.3.1. Emerging collaborations among research labs and pharmaceutical companies
    • 5.1.3.2. Rising demand for personalized medicine among consumers
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent government approval procedures
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product: Rising demand for long-acting insulin drugs among consumers
  • 5.2.2. Application: Increasing application for treatment of type 2 diabetes
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Diabetes Drugs Market, by Product

• 6.1. Introduction
• 6.2. Insulin
  • 6.2.1. Intermediate-Acting Insulin
  • 6.2.2. Long-Acting Insulin
  • 6.2.3. Premixed Insulin
  • 6.2.4. Rapid-Acting Insulin
  • 6.2.5. Short-Acting Insulin
• 6.3. Non-Insulin Injectable Drugs
  • 6.3.1. Amylin Analogs
  • 6.3.2. GLP-1 Receptor Agonists
• 6.4. Oral Drug
  • 6.4.1. Biguanides
  • 6.4.2. DPP-4 inhibitors
  • 6.4.3. SGLT-2 inhibitors
  • 6.4.4. Sulfonylureas
  • 6.4.5. Thiazolidinediones

7. Diabetes Drugs Market, by Application

• 7.1. Introduction
• 7.2. Gestational Diabetes
• 7.3. Type 1 Diabetes
• 7.4. Type 2 Diabetes

8. Diabetes Drugs Market, by Distribution Channel

• 8.1. Introduction
• 8.2. Hospital Pharmacies
• 8.3. Online Pharmacies
• 8.4. Retail Pharmacies

9. Americas Diabetes Drugs Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Diabetes Drugs Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Diabetes Drugs Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Eli Lilly gains approval for diabetes drug Tirzepatide in China
  • 12.3.2. Sanofi India launches Soliqua for Type 2 diabetes and obesity, aiming to simplify treatment and improve compliance
  • 12.3.3. Lupin secures USFDA approval for a generic diabetes drug, targets USD 5 million annual US market with competitive pricing and strategic expansion
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Astellas Pharma Inc.
• 3. AstraZeneca PLC
• 4. Baxter International, Inc.
• 5. Bayer AG
• 6. Biocon Limited
• 7. Bioton S.A.
• 8. Boehringer Ingelheim International GmbH
• 9. Bristol-Myers Squibb Company
• 10. Eli Lilly and Company
• 11. Eva Pharma
• 12. GlaxoSmithKline PLC
• 13. Glenmark Pharmaceuticals Limited
• 14. Gulf Pharmaceutical Industries (Julphar)
• 15. Johnson & Johnson Services, Inc.
• 16. Lupin Limited
• 17. MannKind Corporation
• 18. Merck & Co., Inc.
• 19. MJ Biopharm Pvt. Ltd.
• 20. Novartis AG
• 21. Novo Nordisk A/S
• 22. Oramed Pharmaceuticals Inc.
• 23. Pfizer Inc.
• 24. Sanofi S.A.
• 25. Takeda Pharmaceutical Company Limited
• 26. Tonghua Dongbao Pharmaceutical Co., Ltd.
• 27. Viatris Inc.
• 28. Zydus Lifesciences Limited